Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The primary objective of this study is to assess the safety and efficacy of topical AS101 as treatment for Female Androgenetic Alopecia (FAGA) in menopause women.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rabin Medical Center
• Treatments: Ammonium trichloro(dioxoethylene-O,O'-)tellurate

Criteria

Inclusion Criteria:

• Women in menopause, over 50 years of age.

• Clinically diagnosed for AGA, according to Ludwig scale I-II.

Exclusion Criteria:

• Women treated with chronic medications.

• Use of Minoxidil within 3 months prior to entering study.

• Women who have underwent hair transplantation.

• Use of drugs with androgenic or anti-androgenic effects.

• Any other type of hair loss.